AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06090864 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell infusion
Description: ATLCAR.CD30.CCR4 cells infusion for the eligible subjects after depletion chemotherapy.
Study NCT06053112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New infant formula with 6 HMOs blend
Description: Infants are fed with HMO formula from the date of enrollment to the age of 6 months, exclusive formula feeding until the age of 4 months.
Study NCT06053112 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard infant formula without 6 HMOs blend
Description: Infants are fed with standard formula from the date of enrollment to the age of 6 months, exclusive formula feeding until the age of 4 months.
Study NCT05952011 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left stellate ganglion block
Description: patients will be positioned with head in midline position and mild extension of the neck. Cricoid cartilage will be identified by midline palpation of the neck and a 12 mega hertz ultrasound probe will be used. The airway will be identified by the shadow of the cricoid cartilage at the level of C6 vertebrae. The probe will be moved laterally to identify internal jugular vein, carotid artery and thyroid. Depth of ultrasound field will be adjusted to include the transverse process of the C6 vertebra. Following complete aseptic precautions, an echogenic insulated needle 5 cm long will be inserted under ultrasound guidance and directed toward the transverse process of the C6 vertebra. After the needle tip will make contact with the transverse process, it will be withdrawn 2 mm and 8 ml of 0.25% bupivacaine will be injected.
Study NCT04886544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YVOIRE Y-Solution 720
Description: Hyaluronic acid dermal filler
Study NCT05419128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PartnerCHESS
Description: The following ABCT services, from PartnerCHESS, will be available in the FamCHESS-C app but not in ACHESS-C:~ABCT tutorials. Interactive e-learning modules explaining key ABCT skills. Agreements between drinker and partner to follow key principles. Trigger identification and removal. Cravings discussion. Relapse plan. Reminders.
Study NCT05419128 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACHESS
Description: ACHESS-C offers the following, which are also available in FamCHESS-C: Covid content, Instant Library, Discussion Groups, Personal Stories, Location Monitor, Surveys and Ecological Momentary Assessments, Guided Relaxation, Healthy Activities, Crisis Button, Skills Reminders
Study NCT06375473 — intervention group
Intervention type: DRUG
Intervention: Irinotecan liposome II combination therapy regimen
Description: Irinotecan liposome II combination therapy regimen
Study NCT05352061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for Syndemics and Adherence Factors
Description: Each hour-long session is conducted via zoom or in person with a study clinician. Sessions focus on HIV medication adherence, coping with life stressors, and managing other challenging situations (e.g., possible traumatic experiences, drug and alcohol use and sexual behavior) that may affect mental or HIV-related health.
Study NCT06419556 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical Plexus Block
Description: The patient's head was rested on a pillow and turned to the opposite side. A linear probe with higher frequencies was placed transversely over the midpoint of the SCM muscle. The carotid artery was identified and traced upwards to its bifurcation. the probe was then moved laterally to identify the tapering posterolateral end of the SCM muscle. Via an in-plane technique, a 22-gauge, 50 mm needle was advanced underneath the investing fascia of SCM muscle and above the interscalene groove until the pop on piercing the investing fascia was felt.
Study NCT06419556 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Plexus Block
Description: The patient's head was rested on a pillow and turned to the opposite side. A linear probe with higher frequencies was placed transversely over the midpoint of the SCM muscle. The carotid artery was identified and traced upwards to its bifurcation. the probe was then moved laterally to identify the tapering posterolateral end of the SCM muscle. Via an in-plane technique, a 22-gauge, 50 mm needle was advanced underneath the investing fascia of SCM muscle and above the interscalene groove until the pop on piercing the investing fascia was felt.
Study NCT05066594 — intervention group
Intervention type: DEVICE
Intervention: Transoral incisionless fundoplication
Description: The intervention of transoral incisionless fundoplication using the EsophyX (EndoGastric Solutions) system allows, through the endoscopic route, the creation of a cardial neovalve of approximately 270 ° by placing 20-28 polyethylene sutures on the cardial circumference, resulting in an anti-reflux plastic functionally similar to that obtained with the surgical fundoplication.
Study NCT06341296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposome
Description: 70 mg/m\^2 , d1, 14 days per cycle, 8 cycles.
Study NCT06341296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 400mg/m\^2, then 2400mg/m\^2, continuous intravenous infusion for 46-48h, d1-2, 14 days per cycle, 8 cycles.
Study NCT03281681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL-083, Dianhydrogalactitol
Description: VAL-083 given by intravenous infusion with a starting dose of 60 mg/m2 once weekly. If this regimen is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 67 mg/m2 i.v. If the 67 mg/m2 dose is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 75 mg/m2 i.v. once weekly for the remainder of the study. Dosing will be conducted once per week for a total of 16 weeks.
Study NCT06132893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo taken once daily
Study NCT05433662 — intervention group
Intervention type: BEHAVIORAL
Intervention: Pandemic Acceptance and Commitment Therapy (Pan-ACT)
Description: Pan-ACT is a 10-session, closed group, transdiagnostic intervention for older adults.
Study NCT06241313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atogepant
Description: Oral Tablet
Study NCT06341296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV
Description: 400mg/m\^2, d1, 14 days per cycle, 8 cycles.
Study NCT06341296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5mg/kg, d1, 14 days per cycle, 8 cycles.
Study NCT06241313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Oral Tablet
Study NCT06241313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Atogepant
Description: Oral Tablet
Study NCT06241313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Atogepant
Description: Oral Tablet
Study NCT06477653 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dupilumab
Description: Dupilumab is an interleukin-4 receptor alpha antagonist. Dosing for an individual will be determined based on the nature of their residual symptoms and the FDA-approved dosing for that indication.
Study NCT06052618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Pacritinib is administered orally as 200 mg twice daily for a total of 6, 28-day cycles
Study NCT04729959 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT04729959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample and tumor tissue collection
Study NCT04729959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo surgery
Study NCT04729959 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated Stereotactic Radiation Therapy
Description: Undergo FSRT
Study NCT04729959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04729959 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Given IV
Study NCT04294901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direct to patient medication brochure
Description: An EMPOWER medication brochure, adapted to the VA, designed to educate and activate patients. These brochures provide detailed medication information, allow self-testing of indications for use, prompt reflection of experiences with potential side effects, discuss alternative therapies (medication and non-pharmacologic options), and provide a vignette of a patient who successfully stopped the medicine. They were designed for a 6th grade reading level and were based upon theories of patient activation, adult learning, and cognitive dissonance. The visually appealing brochure repeatedly emphasizes that patients should not make any medication changes without first consulting their health care providers.
Study NCT05475743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Informed Movement program
Description: The patients included in the experimental group attended an 8-week Pain Informed Movement program in addition to standard medical care. The program was led by a physical therapist with experience in treating patients with chronic pain. This program consisted of 2 face-to-face sessions per week, and they were asked to complete two sessions at home weekly. The first face-to-face session was a group session with 3-6 participants, and the second face-to-face session was individual. Both sessions lasted approximately 1 h. In the group sessions, pain neuroscience education was conducted. In the individual sessions, an individualized functional exercise program was performed by each patient, as well as relaxation techniques. Patients were asked to perform the functional exercises and relaxation techniques at home. Participants were asked to record their compliance with the program and their progress.
Study NCT05475743 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical care and leaflet education
Description: In addition to standard medical care, patients assigned to this group received a leaflet with information about the main post COVID-19 condition symptoms. This is a control group that was not controlled or monitored by a therapist.
Study NCT05646706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment was continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
Study NCT05646706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
Study NCT05646706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
Study NCT05655312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [203Pb]VMT01
Description: \[203Pb\]VMT01 is administered intravenous (IV) as an imaging agent for SPECT/CT
Study NCT05655312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [212Pb]VMT01
Description: Subjects with positive uptake of \[203Pb\]VMT01 will receive a fixed dose of \[212Pb\]VMT01 administered IV every 8 weeks starting at Cycle 1 Day 1.
Study NCT05655312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: For all combination-therapy cohorts, 480 mg nivolumab will be administered every 4 weeks as an IV infusion.
Study NCT06295809 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV Infusion
Study NCT06295809 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V940
Description: IM injection
Study NCT06295809 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Local resection of cancerous lesions of the skin
Study NCT06295809 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Local resection of cancerous lesions of the skin
Study NCT04781140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg SPN-812
Description: 100mg SPN-812 will be administered once daily and compared to Placebo
Study NCT04781140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered once daily
Study NCT05923190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Description: EV will be administered at standard dose of 1.25 mg/kg IV on days 1 and 8 with pembrolizumab 200 mg IV on day 1 of a 21-day cycle for 6 cycles
Study NCT05923190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enfortumab vedotin
Description: EV will be administered at standard dose of 1.25 mg/kg IV on days 1 and 8 with pembrolizumab 200 mg IV on day 1 of a 21-day cycle for 6 cycles
Study NCT05923190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered on day 1 of a 21-day cycle
Study NCT05381519 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DXP604
Description: 1800mg，IVgtt
Study NCT05381519 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: DXP604
Description: 1800mg，IVgtt
Study NCT04694937 — intervention group
Intervention type: DEVICE
Intervention: heart rate variabilty measured by pulse oximetry
Description: Resting HRV will be measured by Pulse Oximeter BM2000A/Shanghai Berry Electronic Tech Co., Ltd. that is validated for this purpose and is approved by FDA. The measurement, at the patient's fingertip, takes 5 minutes. The measurement will be performed twice - at two consecutive visits at the clinic, as part as the routine follow up of the patient every 3 months.~HRV will be correlated to demographic and metabolic parameters between patients. In order to reveal whether HRV can serve as a predictor to metabolic disease progression or improvement, HRV will be correlated to metabolic parametrers in the same patient at two time-points.
Study NCT06471751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory and Oropharyngeal Muscle Strengthening
Description: Patients will conduct the training at home, 5 days a week for 3 months. They will perform 2 sets of 30 inspirations against resistance (POWERbreathe® K5 , Powerbreathe International Limited, UK), equal to 70% Maximum Inspiratory Pressure (MIP). Patients will be guided for oropharyngeal exercises.~The sessions will be supervised by the investigator every 3 weeks. During sessions with the investigator, sessions recorded in the device will be downloaded to verify compliance. A MIP measurement will be performed to adjust the resistance of the device.
Study NCT05340062 — intervention group
Intervention type: DEVICE
Intervention: bedside sonography
Description: TCD and ONSD sonography twice a day per 2 days
Study NCT04447911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: Empagliflozin 25mg per os once daily for 30 days
Study NCT04447911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo per os once daily for 30 days
Study NCT06447272 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham inspiratory muscle training
Description: This group will receive conventional treatment + sham IMT (with 10% MIP as the training intensity)
Study NCT06447272 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: target inspiratory muscle training
Description: This group will receive conventional treatment + target IMT (the IMT identified as optimal intensity based on the results of our undergoing study).
Study NCT04835428 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment Group: AGN1 LOEP SV Kit
Description: The AGN1 LOEP SV Kit is intended for fixation of pathological fractures of the vertebral body using vertebral augmentation. Following saline lavage to create space, the AGN1 implant material is injected and hardens in situ to augment the fractured vertebral body. The AGN1 implant material is then resorbed and replaced with new bone.
Study NCT04835428 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group: PMMA bone cement
Description: High viscosity PMMA bone cement will be used for vertebral augmentation.
Study NCT06144281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge for PHPC NP Referral
Description: The attending and covering providers for inpatients who have been identified according to the study's inclusion criteria as appropriate for home palliative care services upon hospital discharge will be asked to refer their patient for these services.
Study NCT06482268 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Human induced pluripotent stem cell-derived dopaminergic progenitors (CT1-DAP001)
Description: Investigational PET agents will be synthesized at UCSD and administered to subjects according to the local institutional guidelines. IND applications for these agents are linked with the IND application for the study product, CT1-DAP001. The IND applications for the PET radiopharmaceuticals contains the manufacturing method, specifications, quality testing, clinical usage, and safety and efficacy information for individual PET agents.~Investigational Cell Injector Suniviion needle: The investigational instrument will be used to administer dopaminergic progenitors into the putamen. After aspirating cells, the instrument will be attached to a Leksell stereotactic frame to administer the cells into the brain.
Study NCT05495490 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osseodensification Internal Sinus Lift
Description: The osteotomy for the Osseodensification internal sinus lift begins with the advancement of a twist drill at 800 rpm and saline irrigation to within 1-2 mm of the sinus floor. The osteotomy is then widened by employing a series of osteotomy drills rotating at 800 rpm. Infracture of the sinus has occurred when the final osteotomy drill is advanced with gentle pressure at 100 rpm counterclockwise without irrigation until a bouncing sensation (haptic feedback) occurs. After infracture, the graft material will be injected into the osteotomy site. Using the final osteotomy drill, the graft is guided apically. This procedure is repeated incrementally to raise the membrane. Once sufficient space has been created beneath the antral membrane, the implant will be inserted followed by suturing.
Study NCT05495490 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteotome Internal Sinus Lift
Description: The osteotomy for the Osteotome internal sinus lift will begin with standard drills and saline irrigation to prepare the implant socket with a working length that is 1-2 mm shorter than the residual bone height as determined by radiographic examination. After preparation, a series of osteotomes of varying diameters will be sequentially utilized to widen the osteotomy and elevate the Schneiderian membrane by vertical tapping to create a greenstick fracture. The Valsalva maneuver (nasal blowing test) will be performed to determine the integrity of the Schneiderian membrane. During the osteotomy, the graft material will be injected and slowly placed into the elevated space using osteotomes until the desired depth is reached. Implant placement and suturing will conclude the procedure.
Study NCT05553860 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Speech positioning technique
Description: Speech positioning technique
Study NCT05553860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech positioning technique
Description: Speech positioning technique
Study NCT05069168 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography before and after TAVR
Description: Evaluation of severity of aortic stenosis using :peak velocity ,peak and mean pressure gradient and aortic valve area by continuity equation.-Evaluation of left ventricular dimensions ,volumes and systolic function as assessed by ejection fraction (EF) by m-mode and biplane simpson's method at apical 4 and 2 chambers view Speckle tracking echocardiography(STE) Apical four-, three-, and two-chamber views were used to obtain longitudinal and circumferential strain before and follow-up after TAVR.~cardiac CT :Routine full protocol before TAVR for evaluation and Detection and calculation of left ventricular fibrosis using extracellular volume.~Coronary angiography:evaluate the presence of CAD and calculation of syntax score(SS)
Study NCT05475665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan/Amlodipine
Description: Irbesartan/Amlodipine once daily for 8 weeks
Study NCT05475665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: Irbesartan once daily for 8 weeks
Study NCT05470842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (Dexcom G6)
Description: All participants will be issued with the Dexcom G6 device. The trial team will buy the readers or smartphones and sensors and provide the participants with all the necessary equipment. Participants will be shown how to wear the Dexcom G6 device, which they will be asked to wear for up to 10 days (=the lifespan of one sensor).~There will be no change in the standard care of the participants' diabetes management, during the study period.